Platelet activation in patients with chronic nonvalvular atrial fibrillation

International Heart Journal

Volumn 47, Issue 3, 2006, Pages 371-379

  Yip, Hon Kan ^a   Chang, Li Teh ^b   Sun, Cheuk Kwan ^a   Yang, Cheng Hsu ^a   Hung, Wei Chin ^a   Hang, Chi Ling ^a   Wu, Chiung Jen ^a   Chua, Sarah ^a   Yeh, Kuo Ho ^a   Chang, Hsueh Wen ^c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Nonvalvular atrial filbrillation; Platelet activation

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; WARFARIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EMBOLISM; FEMALE; FLOW CYTOMETRY; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION;

AGED; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTENSION; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; P-SELECTIN; PLATELET ACTIVATION; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33746169361     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.371     Document Type: Article

References (28)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millenmium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
2. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population control in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93-100.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing oonditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9.
4. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321-6.
5. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206. (Review)
6. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
7. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-7. (Review)
8. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-9.
9. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-7.
10. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
11. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
12. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995; 92: 835-41.
13. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factors and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106: 1962-7.
14. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-8. (Review)
15. van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DW, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999; 30: 546-9.
16. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and progaosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
17. Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995; 21: 146-51.
18. Yip HK, Chen SS, Liu JS, et al. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke 2004; 35: 1683-7.
19. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-4.
20. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32: 2559-66.
21. Wolf PA, Dawber TR, Thomas HE, Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978: 28: 973-7.
22. Chen MC, Wu CJ, Yip HK, et al. Left atrial platelet activity with rheumatic mitral stenosis: correlation study of severity and platelet P-selectin expression by flow cytometry. Chest 2003; 124: 1663-9.
23. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.
24. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273-7.
25. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004; 34: 205-9.
26. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005; 20: 120-8.
27. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EKP3179. Circ Res 2002; 90: 770-6.
28. Yip HK, Chang LT, Sun CK, et al. Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J 2006; 70: 31-6.